MedTrace Logo

Equitable Access to COVID-19 Vaccines

NCT04952376 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1722

Last updated 2022-03-18

No results posted yet for this study

Summary

This study will deploy a multimodal pragmatic intervention to improve vaccine uptake in priority populations and address vaccine hesitancy to improve access by using a proactive organized population-based outreach leveraging health information technology with tailored navigation support to address mistrust and social barriers.

Conditions

  • Covid19

Interventions

BEHAVIORAL

SMS delivery of information

Patients are informed via SMS that COVID-19 vaccine doses are available and advised to schedule an appointment. Links to information or phone for scheduling will be provided. Messages mimic the clinic's usual practice of information delivery to patients

BEHAVIORAL

Personalized text message delivery of information

Patients are informed via SMS that COVID-19 vaccine doses are available and advised to schedule an appointment. The SMS message is personalized as a recommendation from the primary care clinician

BEHAVIORAL

Interactive or 2-way SMS delivery of information

This intervention is same as in the Arm 2 using personalized messaging from the PCP. In addition, patients are given interactive or 2-way SMS options to obtain additional information about COVID vaccine and answers to frequently asked questions.

Sponsors & Collaborators

  • Adelante Healthcare

    collaborator UNKNOWN

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Chyke Doubeni, MD, MPH · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2021-06-10
Completion
2021-06-10

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04952376 on ClinicalTrials.gov